Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3208327 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3OPRM1KCNH2 | |
| SCHEMBL17799000 | 1.00 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3OPRM1KCNH2 | |
| Hydrochloric Acid SCHEMBL23752995 | 0.98 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3OPRM1KCNH2 | |
| SCHEMBL1749865 | 0.82 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL26938717 | 0.82 | SLC6A2 (0.70) | SLC6A2SLC6A4SLC6A3OPRM1KCNH2 | |
| SCHEMBL20820408 | 0.82 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL30608311 | 0.82 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL17815802 | 0.82 | SLC6A2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2P2RY14 | |
| SCHEMBL10819294 | 0.81 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL14520923 | 0.81 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-09 | — | — | US | disclosed |
| WO-2015006280-A9 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015006280-A1 | FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | ADDEX PHARMA S.A. (CH) | 2012-07-19 | — | — | US | disclosed |
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159815-A1 | Fused Piperidine Amides as Modulators of Ion Channels | TRPV1, TRPA1, KCNJ2 | SLC6A2 1335/4885SLC6A4 691/4885SLC6A3 1160/4885 |
| US-20120184525-A1 | 1,2,3-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THIER USE FOR THE TREATMENT OF PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS | GRM2, GRM3, GRM1 | SLC6A2 177/4885SLC6A4 138/4885SLC6A3 106/4885 |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | SLC6A2, HTR3C, SLC6A3 | SLC6A2 1/4885SLC6A4 11/4885SLC6A3 3/4885 |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | SLC6A2, NPY5R, SLC6A3 | SLC6A2 1/4885SLC6A4 14/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.